A compensation system for vaccine injuries is needed for diseases such as Ebola

December 01, 2015

As one part of a comprehensive plan to promote vaccine development for diseases of poverty, such as Ebola, there needs to be a plan to lessen the risks of litigation and liability and ensure recipients of vaccines are fairly compensated in the rare instances that they are harmed. A compensation system for vaccine injuries, based on no-fault principles and, most likely, overseen by the World Bank, could represent a solution to this problem argue Amir Attaran and Kumanan Wilson of the University of Ottawa, Ontario, Canada in a Policy Forum article published this week in PLOS Medicine.

The recent devastating Ebola outbreak has revealed myriad systemic deficiencies in health systems, international institutions, drug development and global readiness for public health emergencies. While there are substantial technical challenges in developing vaccines the lack of arrangements for vaccines to be deployed rapidly without hesitation because of liability due to iatrogenic harm also represents a potential barrier for vaccine deployment for future outbreaks.

Solutions to the liability issue include the country experiencing the public health emergency indemnifying the vaccine supplier, or using the United Nations' immunity from lawsuit to shield the vaccine supplier as was done during the H1N1 pandemic. However, the authors argue that a superior option is for the international community to establish a no-fault compensation fund for novel vaccines released on an emergency basis to low-income countries.

The authors conclude, "[w]e think it is not too ambitious in the available time before an Ebola vaccine is available for routine use to create an international no-fault vaccine injury compensation program, disbursed upon the advice of an expert panel agreeing as to causality, and funded through the World Bank's residual influenza trust funds, plus possibly other Ebola-specific contributions. In the intermediate term, such an arrangement should be institutionalized through the World Bank, its access to insurance markets, and its proposed Global Pandemic Emergency Facility. In the long term, countries should be given assistance to devise no-fault compensation systems within their domestic law, so as to obviate the need to manage liability at the international level."
-end-
Policy Forum

Funding:

This work was funded by Canada's Social Sciences and Humanities Research Council and the Canadian Institutes of Health Research. KW has received funding from the World Health Organization. KW has received funding from Sanofi-Pasteur for mobile bar code scanning. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests:

AA holds a Canada Research Chair in Population Health and Global Development Policy. KW is supported by The Ottawa Hospital, Department of Medicine, Ottawa Hospital Research Institute Chair in Public Health Policy.

Citation:

Attaran A, Wilson K (2015) The Ebola Vaccine, Iatrogenic Injuries, and Legal Liability. PLoS Med 12(12): e1001911. doi:10.1371/journal.pmed.1001911

Author Affiliations:

Institute of Population Health, Faculty of Law, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada

Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada

Ottawa Hospital Research Institute, Ottawa, Ontario, Canada

IN YOUR COVERAGE PLEASE USE THIS URL TO PROVIDE ACCESS TO THE FREELY AVAILABLE PAPER:

http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001911

Contact:

Professor Amir Attaran
Faculties of Law and Medicine; University of Ottawa
Ottawa
CANADA
aattaran@uottawa.ca

Dr. Kumanan Wilson
Senior Scientist Ottawa Hospital Research Institute
Department of Medicine, University of Ottawa
Ottawa Hospital Civic Campus
Ottawa,
CANADA
kwilson@ohri.ca

PLOS

Related Ebola Articles from Brightsurf:

Targeting the shell of the Ebola virus
As the world grapples with COVID-19, the Ebola virus is again raging.

Why doesn't Ebola cause disease in bats, as it does in people?
A new study by researchers from The University of Texas Medical Branch at Galveston uncovered new information on why the Ebola virus can live within bats without causing them harm, while the same virus wreaks deadly havoc to people.

Ebola transmission risks would be taken more seriously with ground-up interventions
A study led by the University of Kent's Durrell Institute of Conservation and Ecology (DICE) has found significant differences in disease risk perception and channels of information about Ebola virus disease (EVD) in rural areas and urban centres of Guinea, West Africa.

US inroads to better Ebola vaccine
As the world focuses on finding a COVID-19 vaccine, research continues on other potentially catastrophic pandemic diseases, including Ebola and Marburg viruses.

Ebola antibodies at work
Scientists in Israel and Germany show, on the molecular level, how an experimental vaccine offers long-term protection against the disease.

Half of Ebola outbreaks undetected
An estimated half of Ebola virus disease outbreaks have gone undetected since it was discovered in 1976, according to research published in PLOS Neglected Tropical Diseases.

Protecting those on the frontline from Ebola
Online training developed at the Medical University of South Carolina (MUSC) increased the knowledge of health care workers about effective prevention of Ebola up to 19 percent and reduced critical errors to 2.3 percent in a small MUSC cohort.

Another piece of Ebola virus puzzle identified
A team of researchers have discovered the interaction between an Ebola virus protein and a protein in human cells that may be an important key to unlocking the pathway of replication of the killer disease in human hosts.

How the human immune system protects against Ebola
'The current approach for treatment of filovirus infections with antibody cocktails tested in animal models utilizes the principle of targeting of non-overlapping epitopes.

How to slow down Ebola
The phylogenetic tree of the 2013-2016 Ebola epidemic doesn't just tell us how the Ebola virus was able to evolve: it also reveals which events and preventive measures accelerated or slowed down its spread.

Read More: Ebola News and Ebola Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.